Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refractory status epilepticus.

J M K Murthy1

  • 1Department of Neurology, The Institute of Neurological Sciences, CARE Hospital, Nampally, Hyderabad - 500 001, India. jmkmurthy@satyam.net.in

Neurology India
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Conventional and Ultrasound-assisted Femoral Nerve Motor Conduction Study in Healthy Controls.

Journal of medical ultrasound·2025
Same author

School Children with Epilepsy: A Need for Telehealth Enabled Epilepsy Smart School Program.

Indian journal of pediatrics·2024
Same author

Idiopathic pulmonary vein thrombosis: an under-recognised source of embolic stroke.

Practical neurology·2024
Same author

Spinocerebellar ataxia subtype 40: Report of a case and review of literature.

Parkinsonism & related disorders·2024
Same author

Autosomal Dominant Spinocerebellar Ataxias: The Subtypes.

Neurology India·2020
Same author

Myasthenia Gravis: Do the Subtypes Matter?

Annals of Indian Academy of Neurology·2020
Same journal

A Life in Service of Neuroscience, Healing, and Teaching.

Neurology India·2026
Same journal

IN MEMORIAM.

Neurology India·2026
Same journal

Extensive Diffusion Restriction of White Matter, Midbrain, and Basal ganglia in a Neonate with Refractory Hypoglycemic Seizures.

Neurology India·2026
Same journal

CHD2-Related Developmental Epileptic Encephalopathy and Angelman Syndrome in a Girl: A Double Jeopardy.

Neurology India·2026
Same journal

Cerebral Schistosomiasis Mimicking Multiple Intracranial Metastases.

Neurology India·2026
Same journal

Extrusion of Spinal Implants Through the Overlying Skin: A Rare Epiphenomenon of Metal Allergy.

Neurology India·2026
See all related articles

Refractory status epilepticus (RSE) is a critical condition often caused by delayed treatment, leading to drug resistance. Prompt, aggressive treatment of status epilepticus (SE) is crucial to prevent RSE and improve patient outcomes.

Area of Science:

  • Neurology
  • Critical Care Medicine

Background:

  • Refractory status epilepticus (RSE) is a frequent complication in intensive care settings.
  • Delayed treatment of status epilepticus (SE) is a key risk factor for developing RSE.
  • SE can lead to progressive, time-dependent pharmacoresistance.

Purpose of the Study:

  • To highlight the importance of early and aggressive treatment of SE to prevent RSE.
  • To discuss the management of established RSE, which is associated with increased mortality and morbidity.
  • To review current treatment strategies and emerging evidence for RSE.

Main Methods:

  • Review of existing literature and clinical experience regarding SE and RSE management.
  • Discussion of pharmacoresistance development in SE.

Related Experiment Videos

  • Analysis of treatment options, including coma-inducing agents and newer antiepileptic drugs (AEDs).

    • Main Results:

    • Early termination of SE is the most effective strategy to prevent RSE.
    • Established RSE necessitates more aggressive therapeutic interventions.
    • Limited randomized controlled trials exist for RSE, with most experience in coma-inducing agents.

    Conclusions:

    • Prompt and aggressive treatment of SE is paramount to prevent refractory cases.
    • Management of RSE requires intensive strategies due to associated poor outcomes.
    • Further research, including randomized controlled trials, is needed, with potential roles for newer AEDs.